ImmuneOncia Q1 2026: Operating Loss Continues, Capital Raise Decided

Q1 2026: zero revenue, operating loss of 5.75 billion won, net loss of 5.62 billion won (vs operating loss of 4.57 billion and net loss of 4.44 billion in Q1 2025)
End-Q1 2026: cash & equivalents 8.89 billion won, short-term financial instruments 10.1 billion won; total assets 27.55 billion, equity 23.12 billion (equity down 28.4% from year-end 2025)
In Feb 2026, board resolved rights offering of 16.83 million shares at 4,860 won per share (payment date May 21, listing June 8); expected to raise approximately 81.8 billion won
IMC-001 (PD-L1): Phase 2 NK/T cell lymphoma ORR 79%, received domestic orphan drug designation in Jan 2026; Phase 2 TMB-High solid tumors ongoing
IMC-002 (CD47): Phase 1b in solid tumors ongoing; IMC-201 (CD47xPD-L1): preclinical
Parent Yuhan Corporation holds 65.75%; no related-party transactions
No tax expense or dividends; 2.256 million stock options outstanding

ADVERTISEMENT (250px+)